Infant Bacterial Therapeutics AB (IBT) is a pharmaceutical company dedicated to developing drugs that prevent diseases in premature infants and combat the spread of antibiotic-resistant illnesses. IBT’s primary focus is on IBP-9414, a drug candidate containing Lactobacillus reuteri, a bacterial strain found in breast milk. The aim of IBP-9414 is to reduce the occurrence of necrotizing enterocolitis (NEC) and improve sustained feeding tolerance (SFT) in premature infants. Currently, IBP-9414 is undergoing a pivotal Phase III study for registration. IBT also has other drug candidates, including IBP-1016 for treating gastroschisis, IBP-1118 for preventing retinopathy of prematurity (ROP), and IBP-1122 for eliminating vancomycin-resistant enterococci (VRE) causing hospital acquired infections. By developing these drugs, IBT addresses medical needs that lack available treatments.
View Top Employees from Infant Bacterial Therapeutics ABWebsite | http://www.ibtherapeutics.com |
Revenue | $7 million |
Employees | 18 (15 on RocketReach) |
Founded | 2013 |
Address | Bryggargatan 10, Stockholm, Stockholm County 111 21, SE |
Phone | +46 70 670 12 26 |
Technologies |
JavaScript,
HTML,
PHP
+11 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Biotechnology, Manufacturing, Science and Engineering |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular Infant Bacterial Therapeutics AB employee's phone or email?
The Infant Bacterial Therapeutics AB annual revenue was $7 million in 2024.
15 people are employed at Infant Bacterial Therapeutics AB.
Infant Bacterial Therapeutics AB is based in Stockholm, Stockholm County.
The NAICS codes for Infant Bacterial Therapeutics AB are [32, 325, 32541, 3254].
The SIC codes for Infant Bacterial Therapeutics AB are [283, 28].